Colorectal cancer is the third most common cancer and the second leading cause of cancer-related death in the Unites States. And while colorectal cancer is highly preventable, it is often undetected due to lack of compliance with screening. The FDA’s approval of a new noninvasive colorectal cancer screening test could help in the detection of this devastating cancer.
On Monday, the FDA approved Cologuard (Exact Sciences), a highly accurate stool based colorectal screening test. Previously, stool based screening tests functioned by detecting occult, or hidden, blood in the stool.